{"id":"W4410823043","doi":"10.1200/jco.2025.43.16_suppl.4540","title":"Efficacy of second line (2L) treatment with tivozanib (Tivo) as monotherapy or with nivolumab (Nivo) in patients (pts) with metastatic renal cell carcinoma (mRCC) previously treated with an immune checkpoint inhibitor (ICI) combination of ipilimumab (Ipi)/Nivo or vascular endothelial growth factor receptor-tyrosine kinase inhibitor (VEGFR-TKI)/ICI in the phase 3 TiNivo-2 study.","year":2025,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Renal cell carcinoma treatment","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"ca_institutions":"University of Calgary","funders":"","keywords":"Nivolumab; Medicine; Renal cell carcinoma; Metastatic melanoma; Oncology; Immune checkpoint; Internal medicine; Ipilimumab; Cancer research; Immunotherapy; Cancer","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001000724,0.0003879479,0.001027277,0.000171319,0.000153658,0.0005946882,0.0004052642,0.0006031782,0.002072512],"category_scores_gemma":[0.001013945,0.0002510412,0.0007469284,0.0001528862,0.0003828154,0.0005040697,0.000240742,0.001021023,0.0003247394],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0007732732,"about_ca_system_score_gemma":0.0005980452,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0005696757,"about_ca_topic_score_gemma":0.001421797,"domain_scores_codex":[0.9996774,0.0001430874,0.00002203169,0.00007005431,0.00002606431,0.00006134353],"domain_scores_gemma":[0.9993436,0.0001365354,0.0001944919,0.00004031925,0.00001969258,0.0002653587],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.788882,0.02526865,0.03769565,0.0005800384,0.00125352,0.0001646804,0.0002736836,0.002775589,0.02215955,0.000141467,0.001937392,0.1188679],"study_design_scores_gemma":[0.1466484,0.7387584,0.1030387,0.00006553943,0.0008748393,0.0003750898,0.00008439789,0.002496943,0.004841531,0.0001632514,0.002606405,0.00004650536],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9977951,0.0009127223,0.00009370073,0.00008066807,0.00002533613,0.0001606583,0.0003288444,0.00001491312,0.0005880817],"genre_scores_gemma":[0.9980216,0.0003142153,0.0001897274,0.0001991708,0.00004521036,0.0002213525,0.0005736839,0.000004202159,0.000430748],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.002072512,"threshold_uncertainty_score":0.006933272,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.05156941605445359,"score_gpt":0.3628631807210154,"score_spread":0.3112937646665618,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}